Zacks Investment Research on MSN11h
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...
Medical Device Network on MSN12h
FDA tags Becton, Dickinson and Company infusion software recall as Class I
Problematic software has been the cause of multiple infusion pump recalls in the medical device industry over the past few years.
STAT14h
Alnylam drug wins FDA approval for progressive heart disease
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
Novartis1d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Spectral AI Announces Public Filing of Registration Statement for Proposed Initial Public Offering of Spectral IP
Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration in ...
FDA, HHS announce plans to increase testing for heavy metals, contaminates in baby formula
The FDA and HHS announced "Operation Stork Speed" Tuesday, which aims to increase testing for heavy metals and other ...